Literature DB >> 30546610

Rivaroxaban for treatment of intraventricular thrombus in Chagas disease.

Alberto A Las Casas1, Alberto A Las Casas1, Marco Aurélio F Borges2, Sebastião E Melo-Souza2.   

Abstract

Chagas disease leads to congestive heart failure, apical aneurysm, and may cause stroke or systemic embolism for intraventricular thrombus. We present a case of a 61-year-old man admitted for stroke 5 months after a renal embolism. An intraventricular thrombus was observed, probably the source of the cerebral and renal embolisms. The patient refused warfarin and rivaroxaban was used instead. After 40 days of treatment the thrombus had dissolved, after 20 months of regular use of rivaroxaban no more embolic events were observed. The use of rivaroxaban was effective in preventing embolic events in Chagas disease and intraventricular thrombus. <Learning objective: Warfarin is recommended for stroke prevention in patients with Chagas disease and left ventricular dysfunction or apical aneurysm, even in the absence of thrombus. None of the new oral anticoagulants is recommended in this context. Rivaroxaban was safe and effective in preventing embolic events in a patient with Chagas disease and a ventricular thrombus.>.

Entities:  

Keywords:  Chagas disease; Non-valvular atrial fibrillation; Rivaroxaban; Stroke; Ventricular thrombus

Year:  2015        PMID: 30546610      PMCID: PMC6280695          DOI: 10.1016/j.jccase.2015.10.010

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  10 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

Review 2.  Chagas disease and stroke.

Authors:  Francisco Javier Carod-Artal; Joaquim Gascon
Journal:  Lancet Neurol       Date:  2010-05       Impact factor: 44.182

3.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Walter N Kernan; Bruce Ovbiagele; Henry R Black; Dawn M Bravata; Marc I Chimowitz; Michael D Ezekowitz; Margaret C Fang; Marc Fisher; Karen L Furie; Donald V Heck; S Claiborne Clay Johnston; Scott E Kasner; Steven J Kittner; Pamela H Mitchell; Michael W Rich; DeJuran Richardson; Lee H Schwamm; John A Wilson
Journal:  Stroke       Date:  2014-05-01       Impact factor: 7.914

4.  Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease.

Authors:  Francisco Javier Carod-Artal; Antonio Pedro Vargas; Thomas Anthony Horan; Luiz Guillerme Nadal Nunes
Journal:  Stroke       Date:  2005-04-21       Impact factor: 7.914

5.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

6.  Prevention strategies of cardioembolic ischemic stroke in Chagas' disease.

Authors:  Andréa Silvestre de Sousa; Sérgio Salles Xavier; Gabriel Rodriguez de Freitas; Alejandro Hasslocher-Moreno
Journal:  Arq Bras Cardiol       Date:  2008-11       Impact factor: 2.000

7.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Long-term survival after ischemic stroke in patients with atrial fibrillation.

Authors:  Margaret C Fang; Alan S Go; Yuchiao Chang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Daniel E Singer
Journal:  Neurology       Date:  2014-02-14       Impact factor: 9.910

Review 9.  Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation.

Authors:  Aaron Liew; John W Eikelboom; Martin O'Donnell
Journal:  Curr Opin Cardiol       Date:  2012-07       Impact factor: 2.161

10.  Anticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatran.

Authors:  Christopher J Boos; Ranjit S More
Journal:  Curr Control Trials Cardiovasc Med       Date:  2004-04-22
  10 in total
  1 in total

1.  Right ventricular thrombus, a challenge in imaging diagnostics: a case series.

Authors:  Massimo Barbagallo; Daryl Naef; Pascal Köpfli; Urs Hufschmid; Tilo Niemann; Rolf Gebker; Jürg Hans Beer; Hanane Hireche-Chiakoui
Journal:  Eur Heart J Case Rep       Date:  2021-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.